scholarly journals Erratum

2017 ◽  
Vol 24 (2) ◽  
pp. NP32-NP32
Keyword(s):  
Multiple Sclerosis ◽  
Positron Emission Tomography ◽  
Outcome Measures ◽  
Progressive Multiple Sclerosis ◽  
Emission Tomography ◽  
Position Emission Tomography ◽  
Positron Emission

Moccia M, De Stefano N and Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. Mult Scler 2017; 23: 1614–1626. DOI: 10.1177/1352458517729456. On pages 1614 and 1620 of this article, positron emission tomography was incorrectly spelled as position emission tomography. SAGE and the authors apologise for any confusion.

Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis

1995 ◽  
Vol 132 (2) ◽  
pp. 139-145 ◽  
Author(s):  
H.M.L. Jansen ◽  
A.T.M. Willemsen ◽  
L.G.F. Sinnige ◽  
A.M.J. Paans ◽  
J.M. Hew ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Positron Emission Tomography ◽  
Progressive Multiple Sclerosis ◽  
Emission Tomography ◽  
Positron Emission

Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-11C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole

2011 ◽  
Vol 69 (4) ◽  
pp. 673-680 ◽  
Author(s):  
Bruno Stankoff ◽  
Leorah Freeman ◽  
Marie-Stéphane Aigrot ◽  
Audrey Chardain ◽  
Frédéric Dollé ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Positron Emission Tomography ◽  
Central Nervous System ◽  
Nervous System ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study

2017 ◽  
Vol 24 (4) ◽  
pp. 543-545 ◽  
Author(s):  
Marloes HJ Hagens ◽  
Joep Killestein ◽  
Maqsood M Yaqub ◽  
Guus AMS van Dongen ◽  
Adriaan A Lammertsma ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Positron Emission Tomography ◽  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Emission Tomography ◽  
Positron Emission ◽  
Central Nervous System Penetration ◽  
Relapsing Remitting ◽  
Rapid Effect ◽  
Relapsing Remitting Multiple Sclerosis

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

Sign in / Sign up

Export Citation Format

Share Document